Page last updated: 2024-09-05

lapatinib and Bone Loss, Osteoclastic

lapatinib has been researched along with Bone Loss, Osteoclastic in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bowen, JM; Chung, R; Keefe, DMK; Lee, AMC; Plews, E; Su, YW; Xian, CJ	1

Other Studies

1 other study(ies) available for lapatinib and Bone Loss, Osteoclastic

Article	Year
Individual or combination treatments with lapatinib and paclitaxel cause potential bone loss and bone marrow adiposity in rats. Journal of cellular biochemistry, 2019, Volume: 120, Issue:3 Topics: Adiposity; Animals; Bone Marrow; Bone Morphogenetic Proteins; Bone Resorption; Drug Therapy, Combination; Gene Expression; Genetic Markers; Intercellular Signaling Peptides and Proteins; Lapatinib; Membrane Proteins; Paclitaxel; PPAR gamma; Protein Kinase Inhibitors; Rats; Rats, Wistar; Survivin; Transcription Factors; Tubulin Modulators; Wnt Proteins; Wnt Signaling Pathway	2019

Article

Year

Individual or combination treatments with lapatinib and paclitaxel cause potential bone loss and bone marrow adiposity in rats.

Journal of cellular biochemistry, 2019, Volume: 120, Issue:3

Topics: Adiposity; Animals; Bone Marrow; Bone Morphogenetic Proteins; Bone Resorption; Drug Therapy, Combination; Gene Expression; Genetic Markers; Intercellular Signaling Peptides and Proteins; Lapatinib; Membrane Proteins; Paclitaxel; PPAR gamma; Protein Kinase Inhibitors; Rats; Rats, Wistar; Survivin; Transcription Factors; Tubulin Modulators; Wnt Proteins; Wnt Signaling Pathway

2019